Vectracor

VectraCor, Inc. is a medical device company with “Disruptive Early Detection Technology” in the Cardiology and Emergency Medicine marketplace with worldwide patents granted and over 40 published papers or abstracts. VectraCor is also the parent company of QRS Diagnostics, a manufacturer of PC-based, cardio-pulmonary devices including ECGs and Spirometers (Orbit Portable Spirometer). VectraCor has developed and patented a technology that will differentiate the current mature monitoring market by enhancing the cardiac monitor to incorporate more technology into one device from only 3 leads (5 electrodes). VectraCor’s technology incorporates the world’s first patented “Cardiac Electrical Biomarker” (CEB) for the real-time detection of ECG changes suggestive of an AMI. No other company has patented, developed and marketed a technology of this kind. The VectraplexECG System needs only 5 electrodes (Limbs and V2) to derive a 15-lead ECG in the US and 22 lead ECG in the EU (CE Mark). The VectraplexAMI will be displayed on the cardiac monitor as a number in real-time, in the same manner as the heart rate. VectraCor's VectraplexAMI index is displayed in real-time and may change if the patient unknowingly begins to develop ECG changes suggestive of an AMI, setting up an internal and audible alarm that can result in the display/print-out of the derived 12-22 lead ECG (15 leads in US and pending CE Mark for a derived 22 Lead ECG) and will prompt the user to acquire a standard 12 lead ECG (by adding the 5 additional electrodes from the same system) for interpretation by the physician.